Cocrystal Pharma, Inc. (COCP) financial statements (2021 and earlier)

Company profile

Business Address 19805 N. CREEK PARKWAY
BOTHELL, WA 98011
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments33321922767
Cash and cash equivalents33321922767
Restricted cash and investments0000000
Receivables1111111
Other undisclosed current assets0000000
Total current assets:34332023879
Noncurrent Assets
Operating lease, right-of-use asset0111111
Property, plant and equipment1110000
Intangible assets, net (including goodwill)19191919196565
Goodwill19191919196565
Deposits noncurrent assets0000000
Total noncurrent assets:20202020206666
TOTAL ASSETS:54534043297375
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1232221
Accounts payable1111211
Accrued liabilities0121000
Employee-related liabilities0000000
Debt0000000
Derivative instruments and hedges, liabilities0000000
Other undisclosed current liabilities0000   
Total current liabilities:1332222
Noncurrent Liabilities
Long-term debt and lease obligation0000111
Finance lease, liability0000000
Operating lease, liability0000111
Other undisclosed noncurrent liabilities (0)(0)(0)   
Total noncurrent liabilities:0000111
Total liabilities:2332332
Stockholders' equity
Stockholders' equity attributable to parent53503740267172
Common stock0000000
Additional paid in capital297294278278261258258
Accumulated deficit(245)(243)(241)(237)(235)(187)(186)
Total stockholders' equity:53503740267172
TOTAL LIABILITIES AND EQUITY:54534043297375

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:1010001
Operating expenses(2)(3)(4)(2)(48)(2)(2)
Operating loss:(1)(3)(3)(2)(48)(2)(2)
Nonoperating income (expense)(0)0(0)(0)000
Interest and debt expense(0)(0)(0)(0)   
Other undisclosed income from continuing operations before equity method investments, income taxes0      
Net loss:(1)(3)(3)(2)(48)(2)(2)
Other undisclosed net income (loss) attributable to parent(0)000   
Net loss available to common stockholders, diluted:(1)(3)(3)(2)(48)(2)(2)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(1)(3)(3)(2)(48)(2)(2)
Comprehensive loss, net of tax, attributable to parent:(1)(3)(3)(2)(48)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: